At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 20 enrolled
Drug / intervention
suvorexant +1 moredrug
Likely dose
suvorexant 10 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Role of the Orexin Receptor System in Stress, Sleep and Cocaine Use
The University of Texas Health Science Center, Houston·interventional·Posted May 27, 2016·Updated Dec 11, 2019
In Brief
A Phase 2 clinical trial evaluating suvorexant and Placebo (for suvorexant) for Cocaine Use Disorder and Anxiety. Completed, enrolled 20 participants across 1 site.
Detailed Summary
The purpose of this study is to determine the effectiveness of a medication called suvorexant in reducing anxiety, improving sleep, and reducing cocaine cravings or cocaine use.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsCocaine Use Disorder, Anxiety
CountriesUnited States
CollaboratorsPeter McManus Charitable Trust
Timeline
Phase 2CompletedFinished
2017201820192020202120222023202420252026
Enrollment StartMay 2016
First PostedMay 2016
Primary CompletionNov 2018
TodayJul 2026
First PostedMay 27, 2016
Enrollment StartMay 1, 2016
Primary CompletionNov 15, 2018
TodayJul 2, 2026
Enrollment to primary: 2.5 yearsPosted 10.1 years ago
Interventions
suvorexantdrug
Subjects will receive suvorexant capsules (10 mg week 1, 20 mg week 2), once daily at 10 PM.
Placebo (for suvorexant)drug
Subjects will receive placebo capsules once daily at 10 PM.